Home Ingredients Genistein
Women's HealthMenopause SupportBone Health

Genistein

Glycine max (primary dietary source)
Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Genistein is the principal isoflavone found in soybeans and is one of the most extensively studied phytoestrogens. As a selective estrogen receptor beta-preferring ligand, it produces tissue-selective estrogenic effects that have been investigated for menopausal vasomotor symptoms, postmenopausal bone health, and cardiometabolic markers. The most notable clinical data come from Italian randomized trials using 54 mg per day of genistein aglycone in osteopenic postmenopausal women, showing improvements in bone mineral density, bone turnover markers, hot flash frequency, mood, and select cardiovascular risk markers over 12 to 24 months. Genistein is also widely studied in vitro for effects on prostate and breast cell biology.

Studied Dose Most positive RCTs in postmenopausal women used 54 mg per day of genistein aglycone for 6–24 months, typically with co-administered calcium and vitamin D.
Active Compound Genistein aglycone, an isoflavone phytoestrogen with selective ER-beta preference.

Benefits

Helps maintain bone mineral density

In osteopenic postmenopausal women, 54 mg per day of genistein aglycone over 24 months supported increases in bone mineral density at the lumbar spine and femoral neck and favorable changes in bone turnover markers, helping support skeletal health during the postmenopausal transition.

Supported by Trial 1

Helps reduce menopausal hot flashes

Daily genistein supplementation in early postmenopausal women is associated with progressive reductions in the frequency of hot flushes over 3, 6, and 12 months of use compared with placebo, supporting comfort during the menopause transition.

Supported by Trial 3, Trial 2

Supports mood and quality of life in postmenopause

Two-year randomized data in osteopenic postmenopausal women suggest that daily genistein supplementation supports improvements in quality of life and reductions in depression-related symptoms compared with placebo, supporting overall well-being.

Supported by Trial 3

Supports cardiometabolic risk markers

Trial data show favorable changes in select predictors of cardiovascular risk including lipid and inflammatory markers in osteopenic postmenopausal women receiving genistein, supporting healthy cardiometabolic profiles when used as part of a comprehensive lifestyle approach.

Supported by Trial 1, Trial 3

Provides selective phytoestrogen activity

Genistein preferentially binds estrogen receptor beta, producing tissue-selective effects that may support bone, vasomotor, and cardiovascular outcomes without strong proliferative signaling at ER-alpha-dominant tissues.

Supported by Trial 1, Trial 2

Mechanism of action

1

Selective estrogen receptor beta agonism

Genistein binds estrogen receptors with substantially higher affinity for ER-beta than ER-alpha, producing tissue-selective phytoestrogenic effects that mimic some of estrogen's benefits in bone, vasomotor, and cardiovascular tissues.

2

Bone remodeling balance

Through ER-beta activation in osteoblasts and osteoclasts, genistein supports osteoblast differentiation and inhibits osteoclast-mediated bone resorption, contributing to the observed gains in bone mineral density in postmenopausal trials.

3

Tyrosine kinase and signaling modulation

Beyond receptor binding, genistein inhibits select tyrosine kinases and modulates intracellular signaling cascades, contributing to its anti-proliferative effects in cancer cell models and its broader effects on cellular metabolism.

4

Antioxidant and anti-inflammatory activity

Genistein scavenges reactive oxygen species and modulates inflammatory signaling, contributing to vascular and metabolic effects observed in animal models and in human trials of cardiovascular risk markers.

Clinical trials

1
24-month bone density RCT

Multicenter, randomized, double-blind, placebo-controlled trial; 54 mg/day genistein aglycone vs placebo for 24 months, all participants receiving calcium and vitamin D.

389 osteopenic postmenopausal women with low femoral neck bone mineral density.

At 24 months, genistein recipients showed increases in bone mineral density at the anteroposterior lumbar spine and femoral neck while placebo recipients showed decreases. Favorable changes in bone turnover markers were observed, with an acceptable safety profile over the two-year period.

2
12-month hot flush RCT vs EPT and placebo

Randomized, double-blind, EPT- and placebo-controlled study; 54 mg/day genistein vs estrogen-progestin therapy vs placebo for 12 months.

90 healthy early postmenopausal women aged 47–57.

Compared with placebo, daily hot flushes reduced by a mean of 22% at 3 months, 29% at 6 months, and 24% at 12 months in the genistein group, providing evidence for the use of pure genistein in reducing menopausal vasomotor symptoms.

3
Quality-of-life and depression sub-study

Two-year randomized, double-blind, placebo-controlled study evaluating quality of life and depression symptoms; 54 mg/day genistein with calcium and vitamin D vs placebo.

Osteopenic postmenopausal women enrolled in the multi-center genistein bone study.

Two years of daily genistein in osteopenic postmenopausal women was associated with improvements in quality-of-life scores and reductions in self-reported depression symptoms compared with placebo, supporting mood and well-being benefits alongside skeletal effects.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal complaints such as bloating, gas, or constipation can occur.
Breast tenderness has been reported infrequently with phytoestrogen use.
Rare allergic reactions in soy-sensitive individuals are possible.
Theoretical concerns persist about high-dose use in hormone-sensitive cancers.

Important Drug interactions

May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity.
Theoretical interaction with thyroid hormone replacement; separate dosing recommended.
May affect anticoagulant response; monitor INR with warfarin co-use.
Could compound effects of hormone replacement therapy or oral contraceptives.

More Women's Health Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…

Related articles from our blog

📝 Article
Introducing HepatoBurn: Burn Fat, Rev Up, and Thrive from Within 🌿
In a world awash with quick-fix diet pills and harsh cleanses, HepatoBurn stands out by addressing a less-touted but cri…
June 20, 2025

Frequently asked questions about Genistein

What is the recommended dosage of Genistein?

The clinically studied dose for Genistein is Most positive RCTs in postmenopausal women used 54 mg per day of genistein aglycone for 6–24 months, typically with co-administered calcium and vitamin D.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Genistein used for?

Genistein is studied for helps maintain bone mineral density, helps reduce menopausal hot flashes, supports mood and quality of life in postmenopause. In osteopenic postmenopausal women, 54 mg per day of genistein aglycone over 24 months supported increases in bone mineral density at the lumbar spine and femoral neck and favorable changes in bone turnover markers, helping support skeletal health du…

Are there side effects from taking Genistein?

Reported potential side effects may include: Mild gastrointestinal complaints such as bloating, gas, or constipation can occur. Breast tenderness has been reported infrequently with phytoestrogen use. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Genistein interact with medications?

Known drug interactions may include: May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity. Theoretical interaction with thyroid hormone replacement; separate dosing recommended. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Genistein good for women's health?

Yes, Genistein is researched for Women's Health support. In osteopenic postmenopausal women, 54 mg per day of genistein aglycone over 24 months supported increases in bone mineral density at the lumbar spine and femoral neck and favorable changes in bone turnover markers, helping support skeletal health during the postmenopausal transi…

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D'Anna R, Cannata ML, Corrado F, Adamo EB, Wilson S, Squadrito F. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Annals of Internal Medicine. 2007;Ann Intern Med. 2007 Jun 19;146(12):839-47..PubMedUsed to support: 24-month RCT in 389 osteopenic postmenopausal women showing genistein 54 mg/day increased BMD vs placebo.
  2. Crisafulli A, Marini H, Bitto A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;Menopause. 2004 Jul-Aug;11(4):400-4..PubMedUsed to support: 12-month RCT showing genistein 54 mg/day reduced hot flush frequency vs placebo in early postmenopausal women.
  3. Atteritano M, Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Mazzaferro S, D'Anna R, Cannata ML, Gaudio A, Frisina A, Frisina N, Corrado F, Cancellieri F, Lubrano C, Bonaiuto M, Adamo EB, Squadrito F. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. The Journal of Clinical Endocrinology and Metabolism. 2007;J Clin Endocrinol Metab. 2007 Aug;92(8):3068-75..PubMedUsed to support: Two-year RCT showing genistein 54 mg/day improved select cardiovascular risk markers in osteopenic postmenopausal women.
  4. D'Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, Triolo O, Antico F, Magno C, Salpietro DC, Granese D, Marini H, Squadrito F. Genistein effects on quality of life and depression symptoms in osteopenic postmenopausal women: a 2-year randomized, double-blind, controlled study. Osteoporosis International. 2014;Osteoporos Int. 2014 Apr;25(4):1255-62..PubMedUsed to support: Two-year RCT showing genistein 54 mg/day improved quality of life and reduced depression symptoms in osteopenic postmenopausal women.
  5. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutrition Reviews. 2003;Nutr Rev. 2003 Apr;61(4):117-31..PubMedUsed to support: Review summarizing in vitro, animal, and limited epidemiologic evidence on soy isoflavones including genistein and prostate cancer risk.